Skip to main content
main-content

Zeitschrift

Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology 5/2019

Ausgabe 5/2019

Inhaltsverzeichnis ( 21 Artikel )

13.02.2019 | Original Article | Ausgabe 5/2019

Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model

Kentaro Miyake, Tasuku Kiyuna, Kei Kawaguchi, Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Sintawat Wangsiricharoen, Sahar Razmjooei, Yunfeng Li, Scott D. Nelson, Takashi Murakami, Yukihiko Hiroshima, Ryusei Matsuyama, Michael Bouvet, Sant P. Chawla, Shree Ram Singh, Itaru Endo, Robert M. Hoffman

13.02.2019 | Original Article | Ausgabe 5/2019

Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation

Ou Yamaguchi, Kyoichi Kaira, Atsuto Mouri, Ayako Shiono, Kosuke Hashimoto, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu

13.02.2019 | Original Article | Ausgabe 5/2019

Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay

Lydia Sanchez, Astrid Bacle, Thierry Lamy, Pascal Le Corre

13.02.2019 | Original Article | Ausgabe 5/2019

Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects

Chandra Prakash, Bin Fan, Syed Altaf, Sam Agresta, Hua Liu, Hua Yang

14.02.2019 | Original Article | Ausgabe 5/2019 Open Access

Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer

Toshio Kawata, Mitsuo Higashimori, Yohji Itoh, Helen Tomkinson, Martin G. Johnson, Weifeng Tang, Fredrik Nyberg, Haiyi Jiang, Yusuke Tanigawara

15.02.2019 | Original Article | Ausgabe 5/2019

SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS

Ian Joseph Cohen, Helen Toledano, Jerry Stein, Yehuda Kollender, Eyal Fenig, Osnat Konen, Zvi Bar-Sever, Josephine Issakov, Meora Feinmesser, Smadar Avigad, Shifra Ash

26.02.2019 | Original Article | Ausgabe 5/2019

A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial

Kazuhiro Nishikawa, Kenta Murotani, Kazumasa Fujitani, Hitoshi Inagaki, Yusuke Akamaru, Shinya Tokunaga, Masakazu Takagi, Shigeyuki Tamura, Naotoshi Sugimoto, Tadashi Shigematsu, Takaki Yoshikawa, Tohru Ishiguro, Masato Nakamura, Hiroko Hasegawa, Satoshi Morita, Yumi Miyashita, Akira Tsuburaya, Junichi Sakamoto, Toshimasa Tsujinaka

26.02.2019 | Original Article | Ausgabe 5/2019

Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia

Shaik Mohammad Naushad, Patchava Dorababu, Yedluri Rupasree, Addepalli Pavani, Digumarti Raghunadharao, Tajamul Hussain, Salman A. Alrokayan, Vijay Kumar Kutala

26.02.2019 | Original Article | Ausgabe 5/2019

Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report

Radiation/systemic drug combo in metastatic melanoma
Emmanuelle Couty, Alexis Vallard, Sandrine Sotton, Sarra Ouni, Max-Adrien Garcia, Sophie Espenel, Chloe Rancoule, Majed Ben Mrad, Anne-Catherine Biron, Jean-Luc Perrot, Julien Langrand-Escure, Nicolas Magné

27.02.2019 | Original Article | Ausgabe 5/2019

Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model

Daniel Thorpe, Masooma Sultani, Andrea Stringer

13.02.2019 | Original Article | Ausgabe 5/2019

Determination of melphalan in human plasma by UPLC–UV method

Liusheng Huang, Vincent Cheah, Danna Chan, Florence Marzan, Christopher C. Dvorak, Francesca T. Aweeka, Janel Long-Boyle

08.03.2019 | Original Article | Ausgabe 5/2019

Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer

Wei Zhang, Long Shi, Zhilong Zhao, Pingping Du, Xueshuai Ye, Dongbin Li, Zhenhua Cai, Jinsheng Han, Jianhui Cai

11.03.2019 | Original Article | Ausgabe 5/2019

The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis

Liangfeng Chen, Xiaobing Han, Zhongzhou Hu, Liangxin Chen

13.03.2019 | Original Article | Ausgabe 5/2019

The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men

Masaki Shiota, Naohiro Fujimoto, Shigehiro Tsukahara, Miho Ushijima, Ario Takeuchi, Eiji Kashiwagi, Junichi Inokuchi, Katsunori Tatsugami, Takeshi Uchiumi, Masatoshi Eto

15.03.2019 | Original Article | Ausgabe 5/2019

CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy

Duo Liu, Xiang Li, Xuehua Li, Mingyan Zhang, Juan Zhang, Dan Hou, Zhiqiang Tong, Mei Dong

16.03.2019 | Original Article | Ausgabe 5/2019 Open Access

A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup

Carlo Lancia, Jakob K. Anninga, Matthew R. Sydes, Cristian Spitoni, Jeremy Whelan, Pancras C. W. Hogendoorn, Hans Gelderblom, Marta Fiocco

18.03.2019 | Original Article | Ausgabe 5/2019

Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours

Peng Yuan, Jianzhong Shentu, Jianming Xu, Wendy Burke, Kate Hsu, Maria Learoyd, Min Zhu, Binghe Xu

18.03.2019 | Original Article | Ausgabe 5/2019

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque, Martin Fuchs, Jorg Trojan, Mark Kozloff, Francesca Simionato, Ann Cleverly, Claire Smith, Shuaicheng Wang, Michael Man, Kyla E. Driscoll, Shawn T. Estrem, Michael M. F. Lahn, Karim A. Benhadji, Josep Tabernero

13.02.2019 | Short Communication | Ausgabe 5/2019

Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38

Mariko Iwase, Ken-ichi Fujita, Yuki Nishimura, Natsumi Seba, Yusuke Masuo, Hiroo Ishida, Yukio Kato, Yuji Kiuchi

27.02.2019 | Short Communication | Ausgabe 5/2019

Eligibility criteria for phase I clinical trials: tight vs loose?

Laeeq Malik, David Lu

04.03.2019 | Letter to the Editor | Ausgabe 5/2019

The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma

Nicolas Albin, Adrien Monard, Jérémy Lapiere

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise